BioPharmX (BPMX) Stock: Climbing On Trial Enrollment

BioPharmX Corp (NYSEAMERICAN: BPMX) is climbing in the market this morning, and for good reason. The comapny announced news with regard to trial enrollment, exciting investors and sending the stock for the top. Today, we’ll talk about:

  • The trial enrollment news;
  • what we’re seeing from BPMX stock as a result; and
  • what we’ll be watching for ahead.

BPMX Announces Trial Enrollment Completion

As mentioned above, BioPharmX is up big in the market this morning after announcing trial enrollment news. In a press release issued early this mroning, the company said that it has compelted enrollment in a Phase 2b clinical trial.

During the trial, BPMX is assessing BPX-04. The treatment is a novel topical gel formulation of fully solubilized minocycline that is being assessed as a potential treatment option for papulopustular rosacea.

In the release, the company said that the trial is a randomized, double-blined, vehicle controlled study. Complete enrollment in the trial includes 207 patients with moderate-to-severe papulopustular rosacea.

Through the study, the company intends on evaluating the safety and efficacy of once daily application of BPX-04 compared to a vehicle control over 12 weeks. The primary endpoint of the trial is to display a mean change in the number of facial inflammatory lesions of rosacea from baseline to week 12.

In a statement, David Tierney, CEO at BPMX, ahd the following to offer:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

This is an important milestone for our rosacea program and we look forward to reporting topline results from the study later this year. Unlike currently available therapies which may further irritate a patient’s already sensitive skin, BPX-04—which utilizes our proprietary HyantX topical delivery system—was designed to improve the bioavailability of solubilized minocycline and enable a more targeted delivery to minimize irritation. Based on results from earlier studies, we believe that BPX-04 may provide an effective treatment for rosacea while minimizing the unwanted adverse effects associated with oral forms of antibiotics, as well as the tolerability limitations of topical treatments, thereby addressing an unmet need for 16 million patients in the US alone.

What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of BioPharmX, the news proved to be overwhelmingly positive. After all, with trial enrollment complete, the company is moving forward int he Phase 2b study, pushing the asset one step closer to potential approval.

So, it’s not surprising to see that excited investors are pushing the stock on a run for the top. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:38), BPMX is trading at $0.11 per share after a gain of $0.0091 per share or 8:83% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on BPMX. In particular, we’re interested in following the story surrounding the company’s continued work to bring BPX-04 to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Share Your Thoughts

What do you think of BPMX? Share your thoughts in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment